An innovative approach to the treatment of ccRCC is the combination of subtherapeutic doses of radiation delivered by [177Lu]Lu-DOTA-girentuximab and Programmed Cell Death-1/Cytotoxic T-lymphocyte antigen 4 (PD-1/CTLA-4) immunotherapy. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.